It has been reported that naringin inhibits MDSCs, proinflammatory mediators (GM-CSF/M-CSF, IL-6, TNF-ɑ), and the NF-κB/IL-6/STAT3 cascade in colorectal tissue, reducing the severity of colitis and colorectal adenoma. This evidence concerns the gene IL6 and colitis.